Intensive analysis of two relevant analogues for this project developed deep insight into assets planned indication expansion
These insights were leveraged with the global market access team that allowed for a refinement of global and national access strategies
A large biotech company, was developing a novel monoclonal antibody in the treatment of multiple rare blood disorders. To inform their strategy, they needed a price estimate of their main comparator, intravenous immunoglobulins (IVIG).
In advance of an upcoming indication expansion for their advanced oncology product, Inbeeo’s client needed to understand the potential implications on HTA, pricing and market access, across the EU5 and US.
HOW WE APPROACHED THE CHALLENGE
Following a landscape review and mapping against key proximity indicators, Inbeeo identified two key product analogues suitable for a deep-dive review.
This involved an intensive analysis of regulatory timelines and decisions, national and regional HTA decisions, reimbursement, and the funding and coverage status.
Price evolutions were mapped against population expansions, and potential net prices were triangulated.Key insights and targeted recommendations were extracted following a synthesis of all analyses.